GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease
March 03, 2015 at 09:02 AM EST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the publication of results from a randomized, placebo-controlled Phase 2 ...
